Adam Escalante is currently the US Vyndamax Competitive & Lifecycle Management Lead at Pfizer, a position held since 2024. Previously, they served as the Director of US Oncology, managing BRAFTOVI and MEKTOVI for melanoma, and held roles including Senior Manager of US Oncology and Marketing Rotational Manager at Pfizer. Adam also led the US Melanoma strategy and indication at Pfizer from 2022 to 2024, and worked as a consultant at Enterprise Analysis Corporation from 2014 to 2016. Their earlier experience includes positions as a Research Associate at Regeneron Pharmaceuticals and a Research Assistant at Cornell University. Adam earned an MBA from Columbia Business School and a Bachelor's Degree in Molecular and Cellular Biology from Cornell University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices